Turnstone teams up with Moffitt to race TIL cell therapies into the clinic
Turnstone teams up with Moffitt to race TIL cell therapies [...]
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death
FDA halts phase 1b Kura Oncology trial in acute myeloid [...]
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet ntaylor [...]
Kymera’s first-in-class protein degrader shows potential to boost cancer immunotherapy
Kymera’s first-in-class protein degrader shows potential to boost cancer immunotherapy [...]
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trial
Acorda CMO hits the exit, landing Pharnext job with oversight [...]
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Rafael resets after phase 3 flop, parting ways with 5 [...]
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?
AstraZeneca, after years of delays and spiraling costs, opens Cambridge [...]
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus
Vaccibody, now Nykode, celebrates new name with a Regeneron deal [...]
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
GlaxoSmithKline takes aim at NASH, penning a $1B pact with [...]
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen [...]